{"id":104,"date":"2020-04-24T20:15:44","date_gmt":"2020-04-24T20:15:44","guid":{"rendered":"https:\/\/neoaptamers.com\/?page_id=104"},"modified":"2025-05-07T10:11:18","modified_gmt":"2025-05-07T14:11:18","slug":"publications","status":"publish","type":"page","link":"https:\/\/neoaptamers.com\/fr\/publications\/","title":{"rendered":"Publications"},"content":{"rendered":"
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Publications sur les Aptam\u00e8res<\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

NeoVentures est d\u00e9di\u00e9 \u00e0 aider nos clients \u00e0 la fois dans la publication de leurs articles et dans la protection de leur propri\u00e9t\u00e9 intellectuelle gr\u00e2ce \u00e0 la protection par brevet. Notre entreprise propose une gamme compl\u00e8te de services m\u00e9ticuleusement con\u00e7us pour renforcer les activit\u00e9s de recherche de nos clients.<\/p>

Votre succ\u00e8s en recherche est notre priorit\u00e9, soulign\u00e9 par notre engagement \u00e0 aider \u00e0 la publication d'articles et \u00e0 renforcer votre propri\u00e9t\u00e9 intellectuelle gr\u00e2ce \u00e0 des mesures de brevet strat\u00e9giques.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t
<\/div>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tArticles<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tBrevets<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Articles<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A new method for the reproducible development of aptamers (Neomers). <\/strong>Meehan C, Hamilton EL, Mansour CG, Lecocq S, Drake CJ, Rodrigues E, Penner G (2025) PLoS One.<\/p>

R\u00e9sum\u00e9<\/p>

The development of aptamers has been almost exclusively performed based on the SELEX method since their inception. While this method represents a powerful means of harnessing the in vitro evolution of sequences that bind to a given target, there are significant constraints in the design. The most significant constraint has been the reliance on counter selection on off-targets to drive specificity. Counter selection has not been as effective at driving aptamer specificity as the presence of immune tolerance, the capacity of the immune system to remove antibodies that bind to host targets, is for antibody development. This deficiency has constrained the commercial efficacy of aptamers to date. These limitations have been addressed with our design of a novel platform for aptamer identification. This new design is based on what we refer to as a Neomer library with sixteen random nucleotides interspersed with fixed sequences. The fixed sequences are designed to minimize the potential for hybridization, such that secondary structure is driven by the random nucleotides. The use of sixteen random nucleotides reduces the possible library sequences to 4.29 \u00d7\u2009 109<\/sup>. This enables the application of the same sequences to either the same target or different targets while maintaining a high level of structural diversity. In effect, this introduces the capacity for reproducibility in aptamer selection and an in-silico approach to replicating immune tolerance. We provide here an overview of the new method and a description of the performance of aptamers selected for interleukin 6 developed using this approach.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A reproducible approach for the use of aptamer libraries for the identification of Aptamarkers for brain amyloid deposition based on plasma analysis. <\/strong>Meehan C, Lecocq S, Penner G (2024) PLoS One.<\/p>

R\u00e9sum\u00e9<\/p>

An approach for the agnostic identification and validation of aptamers for the prediction of a medical state from plasma analysis is presented in application to a key risk factor for Alzheimer\u2019s disease. brain amyloid deposition. This method involved the use of a newly designed aptamer library with sixteen random nucleotides interspersed with fixed sequences called a Neomer library. The Neomer library approach enables the direct application of the same starting library on multiple plasma samples, without the requirement for pre-enrichment associated with the traditional approach. Eight aptamers were identified as a result of the selection process and screened across 390 plasma samples by qPCR assay. Results were analysed using multiple machine learning algorithms from the Scikit-learn package along with clinical variables including cognitive status, age and sex to create predictive models. An Extra Trees Classifier model provided the highest predictive power. The Neomer approach resulted in a sensitivity of 0.88. specificity of 0.76. and AUC of 0.79. The only clinical variables that were included in the model were age and sex. We conclude that the Neomer approach represents a clear improvement for the agnostic identification of aptamers (Aptamarkers) that bind to unknown biomarkers of a medical state.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

A blind trial of Aptamarker prediction of brain amyloid based on plasma analysis<\/strong>.<\/strong>Lecocq, S., Bastos, F., Silva, M., Meehan, C., Castro, R., Cunha, J., Silva, A. C., Ruano, L., Penner, G. (2023). medRxiv.<\/p>

R\u00e9sum\u00e9<\/p>

This study presents a blinded analysis of plasma samples from the FACE cohort in Portugal, applying the Aptamarker platform to predict amyloid status as confirmed by PET imaging. The results support the reproducibility and translational applicability of aptamer-based assays for non-invasive detection of Alzheimer\u2019s pathology, with high predictive accuracy.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Aptamarker prediction of brain amyloid-\u03b2 status in cognitively normal individuals at risk for Alzheimer’s disease<\/strong>. <\/strong>Penner, G., Lecocq, S., Chopin, A., Vedoya, X., Lista, S., Vergallo, A., Cavedo, E., Lejeune, F. X., Dubois, B., Hampel, H., INSIGHT-preAD study group<\/em>, & Alzheimer Precision Medicine Initiative (APMI)<\/em> (2021). PLOS ONE, 16(1), e0243902.<\/p>

R\u00e9sum\u00e9<\/p>

Reliable non-invasive biomarkers are urgently needed to identify Alzheimer\u2019s disease (AD) pathology in cognitively normal individuals. In this study, we used Aptamarker technology to screen for blood biomarkers predictive of brain amyloid-\u03b2 (A\u03b2) status. Our results demonstrate that aptamer-based blood testing has potential to predict brain A\u03b2 burden in at-risk populations with high accuracy, paving the way for early-stage AD diagnostics.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Blood-based diagnostics of Alzheimer’s disease<\/strong>.<\/strong>Penner, G., Lecocq, S., Chopin, A., Vedoya, X., Lista, S., Vergallo, A., Lejeune, F. X., & Hampel, H. (2019). Expert Review of Molecular Diagnostics, 19(7), 613\u2013621.
<\/strong><\/p>

R\u00e9sum\u00e9<\/p>

The development of reliable blood-based biomarkers for Alzheimer’s disease (AD) represents a significant step toward accessible and non-invasive diagnosis. This review explores the state of current blood-based biomarker technologies, emphasizing aptamer-based detection strategies. The potential of these technologies to revolutionize early detection, patient stratification, and monitoring of disease progression is discussed.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Les aptam\u00e8res en tant que biomarqueurs pour les troubles neurologiques. Preuve de concept chez les souris transg\u00e9niques.<\/strong> Lecocq, S., Spinella, K., Dubois, B., Lista, S., Hampel, H., Penner, G. (2018). PLOS ONE.<\/p>

R\u00e9sum\u00e9<\/p>

This proof-of-concept study evaluates aptamers as novel biomarkers for neurodegenerative disease. Using transgenic mouse models of Alzheimer\u2019s disease, the research demonstrates that aptamer-based detection offers specificity and sensitivity in identifying disease-associated molecular changes in plasma. The findings highlight the potential of aptamer technology for future diagnostic development.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

D\u00e9veloppement de nouveaux aptam\u00e8res pour la quantification des particules de lipoprot\u00e9ines de faible densit\u00e9. <\/strong>Klapak D, Broadfoot S, Penner G, Singh A, Inapuri E (2018) PLoS ONE.<\/p>

R\u00e9sum\u00e9<\/p>

Les maladies cardiovasculaires (MCV) restent la principale cause de d\u00e9c\u00e8s dans le monde. Le cholest\u00e9rol des lipoprot\u00e9ines de basse densit\u00e9 (LDL-C) est couramment utilis\u00e9 pour l'\u00e9valuation du risque de MCV ; cependant, des recherches r\u00e9centes ont montr\u00e9 que le nombre de particules de LDL (LDL-P) est un indicateur plus sensible du risque de MCV que le LDL-C et le cholest\u00e9rol des lipoprot\u00e9ines non-hautement densit\u00e9 (HDL-C). Nous d\u00e9crivons ici cinq aptam\u00e8res d'ADN monocat\u00e9naire avec des constantes de dissociation dans la plage des picomoles sp\u00e9cifiques au LDL-P et \u00e0 ses sous-fractions. De plus, un ensemble de s\u00e9quences antisens a \u00e9t\u00e9 d\u00e9velopp\u00e9 et caract\u00e9ris\u00e9, capable de se lier aux meilleurs aptam\u00e8res et de subir un d\u00e9placement par le LDL-P pour une utilisation dans un test de diagnostic simple et abordable.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Les aptam\u00e8res en tant que biomarqueurs pour les troubles neurologiques. Preuve de concept chez les souris transg\u00e9niques.<\/strong>. Lecocq S, Spinella K, Dubois B, Lista S, Hampel H, Penner G (2018) PloS One.<\/p>

R\u00e9sum\u00e9<\/p>

Le processus de s\u00e9lection d'aptam\u00e8res contre le s\u00e9rum sanguin conduit \u00e0 des biblioth\u00e8ques profondes de s\u00e9quences oligonucl\u00e9otidiques se liant \u00e0 diff\u00e9rentes \u00e9pitopes dans le sang. Dans cette \u00e9tude, nous avons d\u00e9velopp\u00e9 une biblioth\u00e8que d'aptam\u00e8res enrichie en effectuant une s\u00e9lection positive contre un pool d'\u00e9chantillons de s\u00e9rum sanguin de souris transg\u00e9niques (P301S) portant le g\u00e8ne humain tau et une s\u00e9lection n\u00e9gative contre un pool de s\u00e9rum sanguin de souris s\u00e9gr\u00e9gante n\u00e9gative (sauvage). Nous avons d\u00e9montr\u00e9 qu'une grande proportion des s\u00e9quences d'aptam\u00e8res observ\u00e9es avec l'analyse de s\u00e9quence de nouvelle g\u00e9n\u00e9ration (NGS) \u00e9taient les m\u00eames des cycles de s\u00e9lection 5 et 6. Dans une deuxi\u00e8me \u00e9tape, nous avons appliqu\u00e9 des aliquotes de la biblioth\u00e8que enrichie du cycle de s\u00e9lection 5 au s\u00e9rum sanguin de 16 souris individuelles pour un seul cycle de s\u00e9lection. Chacune de ces biblioth\u00e8ques individuelles a \u00e9t\u00e9 caract\u00e9ris\u00e9e par une analyse NGS et les changements de fr\u00e9quence relative des aptam\u00e8res chez les souris transg\u00e9niques par rapport aux souris sauvages ont \u00e9t\u00e9 utilis\u00e9s pour construire une empreinte diagnostique de l'effet de l'action du g\u00e8ne transg\u00e9nique sur la composition du s\u00e9rum sanguin. Cette \u00e9tude sert de mod\u00e8le pour des applications similaires avec des sujets humains.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Aptam\u00e8res am\u00e9lior\u00e9s pour le diagnostic et le traitement potentiel du cancer HER2-positif.<\/strong> Gijs, Gregory Penner , Garth B. Blackler , Nathalie R.E.N. Impens, Sarah Baatout , Andr\u00e9 Luxen\u00a0 and An M. Aerts,\u00a0Pharmaceuticals 2016, 9, 29;<\/p>

R\u00e9sum\u00e9<\/p>

Les aptam\u00e8res fournissent une source potentielle de mol\u00e9cules de ciblage alternatives pour les diagnostics et les th\u00e9rapies existantes bas\u00e9es sur les anticorps. Dans ce travail, nous avons s\u00e9lectionn\u00e9 de nouveaux aptam\u00e8res d'ADN ciblant le r\u00e9cepteur HER2 par une approche SELEX sur cellules enti\u00e8res adh\u00e9rentes. Des aptam\u00e8res individuels ont \u00e9t\u00e9 identifi\u00e9s par s\u00e9quen\u00e7age de nouvelle g\u00e9n\u00e9ration et analyse bioinformatique. Deux aptam\u00e8res, HeA2_1 et HeA2_3, ont montr\u00e9 une liaison \u00e0 la prot\u00e9ine HER2 avec des affinit\u00e9s dans la plage des nanomoles. De plus, les deux aptam\u00e8res \u00e9taient capables de se lier avec une grande sp\u00e9cificit\u00e9 aux cellules surexprimant HER2 et aux \u00e9chantillons de tissus tumoraux HER2-positifs. De plus, nous avons d\u00e9montr\u00e9 que l'aptam\u00e8re HeA2_3 \u00e9tait internalis\u00e9 dans les cellules canc\u00e9reuses et avait un effet inhibiteur sur la croissance et la viabilit\u00e9 des cellules canc\u00e9reuses. En fin de compte, nous avons s\u00e9lectionn\u00e9 de nouveaux aptam\u00e8res d'ADN avec un grand potentiel pour le diagnostic et le traitement \u00e9ventuel du cancer HER2-positif.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Selection, activity, and nuclease stabilization of cross-neutralizing DNA aptamers targeting HSV-1 and HSV-2.<\/strong> Schump MD, Bernstein DI, Bravo FJ, Neff CP., Virology. 2024; 589.<\/p>

R\u00e9sum\u00e9<\/p>

Cross-neutralizing aptamers targeting both HSV-1 and HSV-2 were developed by selecting against the ectodo\u00ad mains of glycoprotein D (gD) from both viruses in parallel as well as sequentially using the SELEX method. Since gD facilitates viral invasion, sterically blocking the host-receptor interaction prevents infection. Candidate aptamers were screened, and lead aptamers were identified that exhibited exceptional neutralizing activity against both viruses in vitro. The specificity of the aptamers was confirmed by comparing their activity to scrambled versions of themselves. Modifications of the lead compounds were tested to define critical motifs to\u00a0guide development. Stability of the aptamers was increased using phosphorothioate backbone linkages, and 2<\/span>\u2019<\/span>methoxy substitutions of terminal and key internal bases. Aptamers were applied in a guinea pig vaginal HSV-2 infection model and found to reduce both the viral load of infected animals and the severity of the resulting disease. These results suggest that cross-neutralizing aptamers can be developed into on-demand antiviral in\u00aderventions effective against both HSV-1 and HSV-2.<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

D\u00e9termination de l'ochratoxine A avec un aptam\u00e8re d'ADN. <\/strong>Cruz-Aguado JA, Penner G.,J Agric Food Chem.<\/span> 2008 Nov 26;56(22):10456-61<\/p>

R\u00e9sum\u00e9<\/p>

Ce travail d\u00e9crit l'identification d'un aptam\u00e8re qui se lie avec une grande affinit\u00e9 et sp\u00e9cificit\u00e9 \u00e0 l'ochratoxine A (OTA), une mycotoxine pr\u00e9sente dans le bl\u00e9 et d'autres produits alimentaires, ainsi qu'une m\u00e9thode de d\u00e9tection quantitative de l'OTA bas\u00e9e sur l'utilisation de cet aptam\u00e8re. Les aptam\u00e8res sont des oligonucl\u00e9otides monocat\u00e9naires s\u00e9lectionn\u00e9s in vitro pour se lier \u00e0 des cibles mol\u00e9culaires. L'aptam\u00e8re s\u00e9lectionn\u00e9 dans ce travail a pr\u00e9sent\u00e9 une constante de dissociation dans la plage des nanomoles et ne s'est pas li\u00e9 \u00e0 des compos\u00e9s ayant des structures similaires \u00e0 l'OTA tels que la N-ac\u00e9tylph\u00e9nylalanine ou la warfarine. L'aptam\u00e8re s'est li\u00e9 avec une affinit\u00e9 100 fois moins importante \u00e0 l'ochratoxine B. Les aptam\u00e8res s\u00e9lectionn\u00e9s pourraient \u00eatre utilis\u00e9s pour la d\u00e9termination de quantit\u00e9s de l'OTA de l'ordre du ppb dans des \u00e9chantillons de bl\u00e9 naturellement contamin\u00e9s. Des travaux ult\u00e9rieurs sont en cours pour \u00e9largir l'application d\u00e9montr\u00e9e ici avec le d\u00e9veloppement de capteurs, de colonnes d'affinit\u00e9 et d'autres syst\u00e8mes analytiques pour la d\u00e9termination de cette toxine dans les aliments et les produits agricoles sur le terrain et en laboratoire.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Un test de d\u00e9placement bas\u00e9 sur la polarisation de fluorescence pour la d\u00e9termination de petites mol\u00e9cules avec des aptam\u00e8res.<\/strong> Cruz-Aguado JA, Penner G.Anal Chem.<\/span> 2008 Nov 15;80(22):8853-5<\/p>

R\u00e9sum\u00e9<\/p>

La conversion d'un \u00e9v\u00e9nement de liaison aptam\u00e8re-cible en un signal d\u00e9tectable est une \u00e9tape importante dans le d\u00e9veloppement de capteurs bas\u00e9s sur les aptam\u00e8res. Dans ce travail, nous montrons que le d\u00e9placement d'un oligonucl\u00e9otide marqu\u00e9 par fluorescence de l'aptam\u00e8re par la cible peut \u00eatre d\u00e9tect\u00e9 par la polarisation de fluorescence (FP). Nous avons utilis\u00e9 l'ochratoxine A (OTA), une petite mol\u00e9cule organique (MW = 403), comme cas d'\u00e9tude. Une limite de d\u00e9tection de 5 nM OTA a \u00e9t\u00e9 atteinte. La m\u00e9thode pr\u00e9sent\u00e9e ici pr\u00e9sente un avantage par rapport aux syst\u00e8mes de fluorescence par extinction du fluorophore et \u00e0 d'autres approches de fluorescence \u00e0 l'\u00e9tat stable en ce sens qu'aucune modification de l'aptam\u00e8re ou de la cible n'est n\u00e9cessaire. De plus, le signal est produit par l'\u00e9v\u00e9nement de d\u00e9placement lui-m\u00eame, de sorte qu'aucune autre agr\u00e9gation ou \u00e9v\u00e9nement de conformation n'a \u00e0 \u00eatre pris en compte. Cette m\u00e9thode analytique est particuli\u00e8rement utile pour les petites cibles, car pour les grandes cibles, une mesure directe du changement de polarisation de fluorescence (FP) d'un aptam\u00e8re marqu\u00e9 lors de la liaison peut \u00eatre utilis\u00e9e pour d\u00e9terminer la concentration de la cible. Les r\u00e9sultats pr\u00e9sent\u00e9s ici d\u00e9montrent que les aptam\u00e8res et les oligonucl\u00e9otides marqu\u00e9s \u00e0 faible co\u00fbt peuvent \u00eatre utilis\u00e9s pour la d\u00e9termination rapide, sensible et sp\u00e9cifique de petites mol\u00e9cules par la FP.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

D\u00e9tection des cellules du cancer du sein en utilisant un aptasenseur acoustique sp\u00e9cifique aux r\u00e9cepteurs HER2.<\/strong> Biosensors<\/i>2019<\/b>, 9<\/i>(2), 72<\/p>

R\u00e9sum\u00e9<\/p>

La d\u00e9tection des cellules du cancer du sein est importante pour le diagnostic pr\u00e9coce du cancer. Nous avons utilis\u00e9 la m\u00e9thode de l'acoustique en mode de cisaillement d'\u00e9paisseur (TSM) pour la d\u00e9tection des cellules du cancer du sein SK-BR-3 en utilisant des aptam\u00e8res d'ADN sp\u00e9cifiques aux r\u00e9cepteurs de membrane positifs HER2. Les aptam\u00e8res biotinyl\u00e9s ont \u00e9t\u00e9 immobilis\u00e9s sur la couche de neutravidine chimisorb\u00e9e sur la surface en or du transducteur TSM. L'ajout des cellules a entra\u00een\u00e9 une diminution de la fr\u00e9quence de r\u00e9sonance, fs<\/sub>, et une augmentation de la r\u00e9sistance motrice, Rm<\/sub>En utilisant des nanoparticules d'or (AuNPs) modifi\u00e9es par des aptam\u00e8res, il a \u00e9t\u00e9 possible d'am\u00e9liorer la limite de d\u00e9tection (LOD) qui a atteint 550 cellules\/mL, tandis qu'avec l'amplification, la sensibilit\u00e9 de la d\u00e9tection des cellules SK-BR-3 \u00e9tait de 1574 cellules\/mL. La ligne cellulaire n\u00e9gative pour HER2, MDA-MB-231, n'a pas entra\u00een\u00e9 de changements significatifs de fs<\/sub>Les \u00e9tudes de viabilit\u00e9 ont d\u00e9montr\u00e9 que les cellules sont stables dans les conditions exp\u00e9rimentales utilis\u00e9es pendant au moins 8 heures. Les nanoparticules d'or (AuNPs) n'\u00e9taient pas toxiques pour les cellules jusqu'\u00e0 une concentration de 1 \u03bcg\/mL.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire l'article<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t

Brevets<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Penner, G. (2023). <\/span>Une m\u00e9thode de s\u00e9lection reproductible d'aptam\u00e8res utilis\u00e9e pour identifier des aptam\u00e8res qui se lient \u00e0 des biomarqueurs inconnus.<\/span><\/i>. (WO\/2023\/137558). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Penner, G. (2023). <\/span>Une m\u00e9thode de s\u00e9lection reproductible d'aptam\u00e8res utilisant des espaces de solutions de s\u00e9quence ferm\u00e9s.<\/span><\/i> (WO\/2023\/137559).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mousses, S., Azorsa, D., Feldheim, D. Heil, J., Tran, N., Penner, G. (2023). <\/span>Compositions pour inhiber la croissance de cellules cibl\u00e9es.<\/span><\/i> (WO\/2022\/235971). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mousses, S., Azorsa, D., Feldheim, D. Heil, J., Tran, N., Penner, G. (2023). <\/span>Compositions d'immunoth\u00e9rapie \u00e0 ARN multitargeting.<\/span><\/i> (WO\/2022\/235957). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Mousses, S., Azorsa, D., Feldheim, D. Heil, J., Tran, N., Penner, G. (2023). <\/span>Constructions d'ARNsi pour inhiber l'expression g\u00e9nique dans les cellules canc\u00e9reuses cibl\u00e9es.<\/span><\/i> (WO\/2022\/235975).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Velasquez, J.E., Rupard, S.C., Trejo, A.V., Pitz, A.M., Schmeichel, K.L, Swigart, E.N., Penner, G., et. al. (2023). <\/span>Aptam\u00e8res pour des applications en sant\u00e9.<\/span><\/i> (WO\/2023\/114800). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Velasquez, J.E., Rupard, S.C., Trejo, A.V., Pitz, A.M., Schmeichel, K.L, Swigart, E.N., Penner, G., et. al. (2023). <\/span>Aptam\u00e8res pour les applications en soins de sant\u00e9.<\/span><\/i>. (WO\/2023\/114801). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Velasquez, J.E., Rupard, S.C., Trejo, A.V., Pitz, A.M., Schmeichel, K.L, Swigart, E.N., Penner, G., et. al. (2023). <\/span>Aptam\u00e8res pour les applications en soins de sant\u00e9.<\/span><\/i>. (WO\/2023\/114802). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Shannon, R.J., Penner, G. (2022). <\/span>Aptam\u00e8res contre Clostridium difficile, compositions comprenant des aptam\u00e8res contre Clostridium difficile et m\u00e9thodes d'utilisation de ceux-ci.<\/span><\/i> (WO\/2022\/120004). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Inapuri, E., Singh, A. Penner, G. (2022). <\/span>Aptam\u00e8res pour mesurer les niveaux de lipoprot\u00e9ines.<\/span><\/i>. (WO\/2019\/010341). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Shannon, R.J., Penner, G. (2021). <\/span>Aptam\u00e8res contre le SARS-CoV-2, compositions comprenant des aptam\u00e8res contre le SARS-CoV-2 et m\u00e9thodes d'utilisation de ceux-ci.<\/span><\/i>. (WO\/2021\/202440).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Penner, G. (2021). <\/span>M\u00e9thode de s\u00e9lection d'aptam\u00e8res pour des cibles non li\u00e9es.<\/span><\/i>.<\/b> (WO\/2017\/035666). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Penner, G. (2020). <\/span>D\u00e9tection pr\u00e9coce du pr\u00e9curseur de la maladie d'Alzheimer.<\/span><\/i>. (WO\/2020\/079248).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Velasquez, J.E., Trejo, A.V., Marsh, J.M., Penner, G. (2020). <\/span>Aptam\u00e8res pour des applications de soins capillaires.<\/span><\/i>. (WO\/2020\/005325).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Velasquez, J.E., Trejo, A.V., Penner, G., Jones, S.D. (2020). <\/span>Aptam\u00e8res pour des applications de contr\u00f4le des odeurs.<\/span><\/i>. (WO\/2020\/214784).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Velasquez, J.E., Trejo, A.V., Sagel, P.A., Penner, G. (2019). <\/span>Aptam\u00e8res pour des applications de soins buccaux.<\/span><\/i> (WO\/2019\/032795A1).<\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Penner, G. (2012). <\/span>Une m\u00e9thode pour la s\u00e9lection de ligands d'ADN pour une cible mol\u00e9culaire.<\/span><\/i>. (WO\/2012\/113072). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Cruz-Aguado, J.A., Penner, G. (2011). <\/span>Une m\u00e9thode et un appareil pour la d\u00e9termination de la concentration d'un analyte par \u00e9coulement lat\u00e9ral.<\/span><\/i> (WO\/2011\/032278). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Cruz-Aguado, J.A., Penner, G. (2011). <\/span>M\u00e9thode pour d\u00e9terminer la pr\u00e9sence et la concentration d'analytes en utilisant un ligand d'acide nucl\u00e9ique et un \u00e9l\u00e9ment des terres rares.<\/span><\/i>. (WO\/2011\/014945). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Penner, G., Cruz, J.A. (2009). M\u00e9thode de d\u00e9tection des mycotoxines. (WO\/2009\/086621). <\/span><\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t\t\t\n\t\t\t\t<\/i>\t\t\t<\/span>\n\t\t\t\t\t\t\t\t\tLire le brevet.<\/span>\n\t\t\t\t\t<\/span>\n\t\t\t\t\t<\/a>\n\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t
\n\t\t\t\n\t\t\t\t\t\t<\/span>\n\t\t<\/div>\n\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>","protected":false},"excerpt":{"rendered":"

Aptamer Publications NeoVentures is dedicated to assisting our clients in both the publication of their articles and the safeguarding of their intellectual property through patent protection. Our company offers an all-encompassing array of services meticulously designed to bolster our clients’ research pursuits. Your research success is our priority, underscored by our dedication to aiding in… Lire la suite »Publications<\/span><\/a><\/p>","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"neve_meta_sidebar":"","neve_meta_container":"","neve_meta_enable_content_width":"off","neve_meta_content_width":70,"neve_meta_title_alignment":"","neve_meta_author_avatar":"","neve_post_elements_order":"","neve_meta_disable_header":"","neve_meta_disable_footer":"","neve_meta_disable_title":"","footnotes":""},"class_list":["post-104","page","type-page","status-publish","hentry"],"yoast_head":"\nPublications | Aptamer Resources & Developments | Neoaptamers.com<\/title>\n<meta name=\"description\" content=\"Consult our aptamer resources. Read our peer-reviewed aptamer publications. Educate yourself on aptamer development.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/neoaptamers.com\/fr\/publications\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Publications | Aptamer Resources & Developments | Neoaptamers.com\" \/>\n<meta property=\"og:description\" content=\"Consult our aptamer resources. Read our peer-reviewed aptamer publications. Educate yourself on aptamer development.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/neoaptamers.com\/fr\/publications\/\" \/>\n<meta property=\"og:site_name\" content=\"neoaptamers\" \/>\n<meta property=\"article:modified_time\" content=\"2025-05-07T14:11:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-neoaptamers.com_.png\" \/>\n\t<meta property=\"og:image:width\" content=\"500\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/publications\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/publications\\\/\",\"name\":\"Publications | Aptamer Resources & Developments | Neoaptamers.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\"},\"datePublished\":\"2020-04-24T20:15:44+00:00\",\"dateModified\":\"2025-05-07T14:11:18+00:00\",\"description\":\"Consult our aptamer resources. Read our peer-reviewed aptamer publications. Educate yourself on aptamer development.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/publications\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/neoaptamers.com\\\/publications\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/publications\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/neoaptamers.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Publications\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#website\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"name\":\"Neoaptamers.com\",\"description\":\"Neoventures Biotechnology Inc.\",\"publisher\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/neoaptamers.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#organization\",\"name\":\"NeoVentures Biotechnology Inc.\",\"alternateName\":\"NVB\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"contentUrl\":\"https:\\\/\\\/neoaptamers.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png\",\"width\":500,\"height\":500,\"caption\":\"NeoVentures Biotechnology Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/neoaptamers.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.linkedin.com\\\/company\\\/neoventures-biotechnology-inc-\\\/\",\"https:\\\/\\\/www.reddit.com\\\/user\\\/NeoVenturesBiotech\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@neoaptamers7964\"]}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ublications | Ressources Et D\u00e9veloppements Des Aptam\u00e8res | Neoaptamers.com","description":"Consultez nos ressources sur les aptamers. Lisez nos publications sur les aptamers \u00e9valu\u00e9es par des pairs. Informez-vous sur le d\u00e9veloppement des aptamers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/neoaptamers.com\/fr\/publications\/","og_locale":"fr_FR","og_type":"article","og_title":"Publications | Aptamer Resources & Developments | Neoaptamers.com","og_description":"Consult our aptamer resources. Read our peer-reviewed aptamer publications. Educate yourself on aptamer development.","og_url":"https:\/\/neoaptamers.com\/fr\/publications\/","og_site_name":"neoaptamers","article_modified_time":"2025-05-07T14:11:18+00:00","og_image":[{"width":500,"height":500,"url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-neoaptamers.com_.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/neoaptamers.com\/publications\/","url":"https:\/\/neoaptamers.com\/publications\/","name":"ublications | Ressources Et D\u00e9veloppements Des Aptam\u00e8res | Neoaptamers.com","isPartOf":{"@id":"https:\/\/neoaptamers.com\/#website"},"datePublished":"2020-04-24T20:15:44+00:00","dateModified":"2025-05-07T14:11:18+00:00","description":"Consultez nos ressources sur les aptamers. Lisez nos publications sur les aptamers \u00e9valu\u00e9es par des pairs. Informez-vous sur le d\u00e9veloppement des aptamers.","breadcrumb":{"@id":"https:\/\/neoaptamers.com\/publications\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/neoaptamers.com\/publications\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/neoaptamers.com\/publications\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/neoaptamers.com\/"},{"@type":"ListItem","position":2,"name":"Publications"}]},{"@type":"WebSite","@id":"https:\/\/neoaptamers.com\/#website","url":"https:\/\/neoaptamers.com\/","name":"Neoaptamers.com","description":"Neoventures Biotechnology Inc.","publisher":{"@id":"https:\/\/neoaptamers.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/neoaptamers.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/neoaptamers.com\/#organization","name":"NeoVentures Biotechnology Inc.","alternateName":"NVB","url":"https:\/\/neoaptamers.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/","url":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","contentUrl":"https:\/\/neoaptamers.com\/wp-content\/uploads\/2024\/07\/NeoVentures-Biotechnology-Square-Logo-No-Text-1.png","width":500,"height":500,"caption":"NeoVentures Biotechnology Inc."},"image":{"@id":"https:\/\/neoaptamers.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/neoventures-biotechnology-inc-\/","https:\/\/www.reddit.com\/user\/NeoVenturesBiotech\/","https:\/\/www.youtube.com\/@neoaptamers7964"]}]}},"_links":{"self":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/pages\/104","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/comments?post=104"}],"version-history":[{"count":132,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/pages\/104\/revisions"}],"predecessor-version":[{"id":6234,"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/pages\/104\/revisions\/6234"}],"wp:attachment":[{"href":"https:\/\/neoaptamers.com\/fr\/wp-json\/wp\/v2\/media?parent=104"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}